Pan-cancer Analysis Reveals That TK1 Promotes Tumor Progression by Mediating Cell Proliferation and Th2 Cell Polarization

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2024 Sep 29

PMID 39343871

Authors

Zhecheng Li

Zhaoyi Wu

Xing You

Neng Tang

Affiliations

Soon will be listed here.

Abstract

Background: TK1 (Thymidine kinase 1) is a member of the thymidine kinase family and has been observed to be significantly upregulated in a variety of cancer types. However, the exact roles of TK1 in tumor progression and the tumor immune microenvironment are not fully understood. This study aims to investigate the comprehensive involvement of TK1 in pan-cancer through the utilization of bioinformatics analysis, validation of pathological tissue samples, and in vitro experimental investigations.

Methods: The expression profiles together with diagnostic and prognostic role of TK1 in pan-cancer were investigated though TCGA, TARGET, GTEx, and CPTAC databases. The single-sample gene set enrichment analysis (ssGSEA) and single-cell sequencing datasets were used to examine the relationship between TK1 and immune infiltration. The expression of TK1 were verified in hepatocellular carcinoma (HCC) through qPCR, western blotting and immunohistochemical assays. The proliferative capacity of HCC cell lines was assessed through CCK-8 and colony formation assays, while cytokine levels were measured via ELISA. Furthermore, flow cytometry was utilized to analyze cell cycle distribution and the proportions of Th2 cells.

Results: TK1 was overexpressed in most cancers and demonstrated significant diagnostic and prognostic value. Among the various immune cells in pan-cancer, Th2 cells exhibited the closest association with TK1. Furthermore, the single-cell atlas provided insights into the distribution and proportion of TK1 in immune cells of HCC. In vitro experiments revealed an elevated expression of TK1 in HCC tissue and cell lines, and its role in influencing HCC cell proliferation by regulating G0/G1 phase arrest. Additionally, TK1 in cancer cells was found to potentially modulate Th2 cell polarization through the chemokine CCL5.

Conclusion: TK1 holds immense potential as a biomarker for pan-cancer diagnosis and prognosis. Additionally, targeting the expression of TK1 represents a promising therapeutic approach that can enhance the efficacy of current anti-tumor immunotherapy by modulating Th2 cell polarization and multiple mechanisms.

Citing Articles

Identification of BIRC5 and HMMR as prognostic biomarkers for immune infiltration in prostate cancer.

Tang H, Zhou F, Hu W, Zhang C, Tao J, Xing F Transl Androl Urol. 2024; 13(11):2482-2497.

PMID: 39698582 PMC: 11650346. DOI: 10.21037/tau-24-359.

References

Li Q, Zhang L, Yang Q, Li M, Pan X, Xu J . Thymidine kinase 1 drives hepatocellular carcinoma in enzyme-dependent and -independent manners. Cell Metab. 2023; 35(6):912-927.e7. DOI: 10.1016/j.cmet.2023.03.017. View

Zhang C, Ma S, Hao X, Wang Z, Sun Z . Methylation status of TK1 correlated with immune infiltrates in prostate cancer. Front Genet. 2022; 13:899384. PMC: 9403003. DOI: 10.3389/fgene.2022.899384. View

Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View

Alegre M, Robison R, ONeill K . Thymidine kinase 1 upregulation is an early event in breast tumor formation. J Oncol. 2012; 2012:575647. PMC: 3388419. DOI: 10.1155/2012/575647. View

Tang Y, Li K, Cai Z, Xie Y, Tan X, Su C . HSP90α combined with AFP and TK1 improved the diagnostic value for hepatocellular carcinoma. Biomark Med. 2020; 14(10):869-878. DOI: 10.2217/bmm-2019-0484. View

Chandrashekar D, Bashel B, Balasubramanya S, Creighton C, Ponce-Rodriguez I, Chakravarthi B . UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 2017; 19(8):649-658. PMC: 5516091. DOI: 10.1016/j.neo.2017.05.002. View

Xiao Y, Yu D . Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. 2020; 221:107753. PMC: 8084948. DOI: 10.1016/j.pharmthera.2020.107753. View

Seiwert T, Burtness B, Mehra R, Weiss J, Berger R, Eder J . Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016; 17(7):956-965. DOI: 10.1016/S1470-2045(16)30066-3. View

Hanzelmann S, Castelo R, Guinney J . GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013; 14:7. PMC: 3618321. DOI: 10.1186/1471-2105-14-7. View

10.

Dou Q, Pardee A . Transcriptional activation of thymidine kinase, a marker for cell cycle control. Prog Nucleic Acid Res Mol Biol. 1996; 53:197-217. DOI: 10.1016/s0079-6603(08)60145-2. View

11.

Wu M, Ye M . Transcription factor Dp-1 knockdown downregulates thymidine kinase 1 expression to protect against proliferation and epithelial-mesenchymal transition in cervical cancer. Funct Integr Genomics. 2023; 23(4):301. DOI: 10.1007/s10142-023-01218-6. View

12.

Ott P, Hodi F, Robert C . CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res. 2013; 19(19):5300-9. DOI: 10.1158/1078-0432.CCR-13-0143. View

13.

Cai Q, Zhu M, Duan J, Wang H, Chen J, Xiao Y . Comprehensive Analysis of Immune-Related Prognosis of TK1 in Hepatocellular Carcinoma. Front Oncol. 2022; 11:786873. PMC: 8814100. DOI: 10.3389/fonc.2021.786873. View

14.

Liu C, Wang J, Zhao L, He H, Zhao P, Peng Z . Knockdown of Thymidine Kinase 1 Suppresses Cell Proliferation, Invasion, Migration, and Epithelial-Mesenchymal Transition in Thyroid Carcinoma Cells. Front Oncol. 2020; 9:1475. PMC: 7000458. DOI: 10.3389/fonc.2019.01475. View

15.

von Euler H, Eriksson S . Comparative aspects of the proliferation marker thymidine kinase 1 in human and canine tumour diseases. Vet Comp Oncol. 2011; 9(1):1-15. DOI: 10.1111/j.1476-5829.2010.00238.x. View

16.

Wculek S, Cueto F, Mujal A, Melero I, Krummel M, Sancho D . Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2019; 20(1):7-24. DOI: 10.1038/s41577-019-0210-z. View

17.

Merlo L, Pepper J, Reid B, Maley C . Cancer as an evolutionary and ecological process. Nat Rev Cancer. 2006; 6(12):924-35. DOI: 10.1038/nrc2013. View

18.

Sun J, Wu M, Wang L, Wang P, Xiao T, Wang S . miRNA-21, which disrupts metabolic reprogramming to facilitate CD4 T cell polarization toward the Th2 phenotype, accelerates arsenite-induced hepatic fibrosis. Ecotoxicol Environ Saf. 2022; 248:114321. DOI: 10.1016/j.ecoenv.2022.114321. View

19.

Xie H, Guo L, Wang Z, Peng S, Ma Q, Yang Z . Assessing the Potential Prognostic and Immunological Role of TK1 in Prostate Cancer. Front Genet. 2022; 13:778850. PMC: 9086852. DOI: 10.3389/fgene.2022.778850. View

20.

Sas Z, Cendrowicz E, Weinhauser I, Rygiel T . Tumor Microenvironment of Hepatocellular Carcinoma: Challenges and Opportunities for New Treatment Options. Int J Mol Sci. 2022; 23(7). PMC: 8998420. DOI: 10.3390/ijms23073778. View